Nine candidates applied for a seat at the council of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - including many renowned professors from Germany, Sweden and Austria.
- It's a great honour to have been elected to this elite group. I have dedicated my entire professional career to issues concerning multiple sclerosis. MS has been the subject of all my grants and research work. Council membership means having an impact on future policies, being able to organise congresses and have an influence on internships, scholarships and financing. It also means a great prestige not only for our university, but also for our country. ECTRIMS was established by old EU countries. The leading countries have always been England, France, Italy, Spain and Switzerland. This makes me even more pleased that our effort has been appreciated - Prof. Mycko emphasises.
Prof. Mycko will act as a link between ECTRIMS and the European Medicines Agency (EMA), which provides scientific assessment, supervision and monitoring of the safety of medicinal products for human and veterinary use in the European Union. This is the European equivalent of the FDA in the US.
- All medicines for the Polish market must first be registered in Europe. Currently, we can see a large number of preparations for multiple sclerosis treatment. Hence, good relations with EMA are important to know the requirements and the next steps. A preparation can be called a medicine only upon its certification - Prof. Mycko explains.
Prof. Mycko has been a member of the ECTRIMS Council for many years. He has always been engaged with the council and has been very active. He is the second Pole to be appointed to this prestigious organisation. Before the appointment of Prof. Mycko, Prof. Krzysztof Selmaj, head of the Department of Neurology, University of Warmia and Mazury, was the only representative from Central-Eastern Europe at the council.
Prof. Marcin Mycko is employed at the Department of Neurology, Collegium Medicum, University of Warmia and Mazury.
He has participated in several international scientific internships: at the Harbor Laboratory, USA, at the Ruhr University in Bochum, Germany, at the Ludwig Institute for Cancer Research in Lausanne, Switzerland; at the Albert Einstein Medical College, New York; at the Serono Research Institute in Geneva, Switzerland; at the Harvard University Medical Institute, USA. Prof. Mycko is a member of many scientific organisations. He is on the editorial committee of the Polish Journal of Neurology and Neurosurgery and a member of expert teams at the National Science Centre. He is a regular reviewer of articles in three foreign journals and one Polish scientific journal.
Prof. Mycko manages or participates in ten scientific grants financed by the National Science Centre, the National Centre for Research and Development and the Polish-Swiss research programme. He is the author or co-author of 43 publications published in foreign and Polish scientific journals as well as three scientific books.
The Impact Factor of his scientific output is 224,307 points and the Hirsch Index: 22 (Scopus), 23 (Web of Science). Number of citations is 3456 (Scopus) according to the Web of Science database.
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is a non-profit organisation and an independent representative European-wide organisation devoted to multiple sclerosis (MS). The mission of ECTRIMS is to facilitate communication, create synergies, and promote and enhance research and learning among professionals for the ultimate benefit of people affected by MS.